iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
NATAP HCV Fall 2015 Current Reports / Reading
List/Conference Reports: ICAAC, IDSA, EACS
 
 
  from Jules Levin, NATAP
 
HCV USA/Prevalence 8-9 Million?? - (10/09/15)
 
IDSA: Continued Rising Mortality from Hepatitis C Virus in the United States, 2003-2013 (10/19/15)
 
Treating ALL with HCV is Best Value for Society - New Modeling Study Reports - Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern - (10/15/15)
 
HCV Hospitalizations Costs Increase 291%, estimated healthcare system burden by study at $15 billion/year... - (10/21/15)
 
Risk of Deferring HCV Treatment - CDC CheCS: "All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus" - (10/20/15)
 
EACS: Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients?..... "SVR -reduced incidence of liver-related death and improved overall survival" (10/27/15)
 
EACS: Trends in incidences and risk factors for hepatocellular carcinoma & other liver events in HIV/HCV co-infected individuals from 2001 to 2014: a multi-cohort study - (10/30/15)
 
EACS: No decline in hepatitis C incidence among HIV-positive MSM; an update from the CASCADE Collaboration - (10/30/15)
 
Mortality in HCV/HIV Coinfected Drug Users in Amsterdam Twice that of Drug Users - Temporal trends in mortality among people who use drugs compared with the general Dutch population differ by hepatitis C virus and HIV infection status - (10/28/15)
 
"Treatment is recommended for all patients with chronic HCV infection" - HCV Guidelines Updated Oct 22 2015 - (10/28/15)
 
EACS: TURQUOISE-I STUDY: USE OF OMBITASVIR/PARITAPREVIR/RITONAVIR + DASABUVIR + RIBAVIRIN IN PATIENTS WITH HCV/HIV-1 CO-INFECTION ON STABLE DARUNAVIR-CONTAINING ANTIRETROVIRAL THERAPY (10/27/15)
 
IDSA: Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients (10/15/15)
 
* IDSA: Lack of Drug Interactions Between Boosted and Unboosted TAF-Based Antiretroviral Single-Tablet Regimens (E/C/F/TAF, R/F/TAF) and the anti-HCV Single-Tablet Regimen Ledipasvir/Sofosbuvir (10/13/15)
 
EACS: Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - Results from the German hepatitis C cohort (GECCO) (10/27/15)
 
IDSA: C-EDGE: INTEGRATED ANALYSIS FROM THE PHASE 2/3 STUDIES of ELBASVIR / GRAZOPREVIR in HIV PATIENTS WITH HCV/HIV (10/15/15)
 
IDSA: 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens (10/15/15)
 
IDSA: 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by Black Race (10/15/15)
 
FDA - Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury - (10/28/15)
 
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes - (09/22/15)
 
U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs - (10/07/15)
 
--------------------------
 
Barriers / Cascade
 
IDSA: Pharmacy-based Resource Requirements to Obtain HCV Therapy for HIV/HCV Co-Infected Patients (10/15/15)
 
IDSA: Exploring the Benefits of an Enhanced Social Work Intervention within the HCV Cascade of Care (10/19/15)
 
IDSA: HCV Cascade/Denver - Impact of Interferon-Era HCV Treatment Restrictions on Current Referral and Treatment Trends (10/19/15)
 
IDSA: Gender, Ethnicity, IDU, and Risk for HCV Among New York City Jail Inmates (10/19/15)
 
IDSA: Chicago - Diagnosed, staged and untreated: Hepatitis C fibrosis severity by transient elastography (TE) in an inner city clinic (10/19/15)
 
IDSA: Linkage to Care for Hepatitis C: Creating a Cascade of Care to Identify Gaps at the Individual Hospital Level (Bellevue Hospital-NYC) (10/19/15)
 
IDSA: Hepatitis C Virus (HCV) In Young Suburban Heroin Users In New Jersey; Part Of The Second Wave Of Hepatitis C (10/19/15)
 
IDSA: HCV Cascade/Barriers in Philadelphia - "Meet the Professor: Overcoming barriers to HCV care" (10/21/15)
 
(IWCADRH) 17th Intl Workshop on Comorbidities and Adverse Drug Reactions in HIV Oct 20-22 2015, Barcelona, Spain
 
ICAAC 2015 55th Interscience Conference on Antimicrobial Agents and Chemotherapy September 5-9, 2015, San Diego, CA
 
15th European AIDS Conference (EACS) October 21-24, 2015 Barcelona
 
IDSA/IDWeek October 7-11 2015 San Diego
 

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org